Alexion Pharmaceuticals (ALXN) Price Target Cut to $170.00 by Analysts at Citigroup

Alexion Pharmaceuticals (NASDAQ:ALXN) had its target price cut by research analysts at Citigroup from $173.00 to $170.00 in a research report issued on Friday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s price objective would suggest a potential upside of 56.54% from the company’s current price.

Several other equities analysts have also recently commented on the stock. Zacks Investment Research cut shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. TheStreet cut shares of Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Friday, November 10th. Robert W. Baird raised shares of Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $150.00 price target on the stock in a research report on Monday, December 18th. Royal Bank of Canada increased their price target on shares of Alexion Pharmaceuticals to $166.00 in a research report on Tuesday, October 24th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $170.00 price target on shares of Alexion Pharmaceuticals in a research report on Monday, October 23rd. One analyst has rated the stock with a sell rating, two have issued a hold rating and twenty-one have assigned a buy rating to the company. Alexion Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $153.14.

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded up $0.13 during mid-day trading on Friday, hitting $108.60. The company has a quick ratio of 2.51, a current ratio of 3.10 and a debt-to-equity ratio of 0.34. Alexion Pharmaceuticals has a 12-month low of $96.18 and a 12-month high of $149.34. The stock has a market cap of $24,260.00, a P/E ratio of 55.13, a price-to-earnings-growth ratio of 0.91 and a beta of 1.16.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.09 by $0.39. Alexion Pharmaceuticals had a net margin of 12.48% and a return on equity of 12.94%. The business had revenue of $909.70 million for the quarter, compared to analysts’ expectations of $880.38 million. During the same quarter last year, the company posted $1.26 earnings per share. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. sell-side analysts predict that Alexion Pharmaceuticals will post 6.25 earnings per share for the current year.

In related news, CEO Ludwig Hantson sold 13,245 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $116.31, for a total transaction of $1,540,525.95. Following the transaction, the chief executive officer now owns 131,425 shares in the company, valued at $15,286,041.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Paul J. Clancy sold 6,079 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $116.31, for a total transaction of $707,048.49. Following the transaction, the chief financial officer now owns 95,093 shares in the company, valued at approximately $11,060,266.83. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 28,930 shares of company stock worth $3,378,199. Corporate insiders own 4.35% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Valeo Financial Advisors LLC acquired a new position in shares of Alexion Pharmaceuticals during the third quarter valued at approximately $147,000. Dupont Capital Management Corp acquired a new position in shares of Alexion Pharmaceuticals during the third quarter valued at approximately $156,000. BT Investment Management Ltd acquired a new position in shares of Alexion Pharmaceuticals during the third quarter valued at approximately $165,000. Beacon Investment Advisory Services Inc. acquired a new position in shares of Alexion Pharmaceuticals during the third quarter valued at approximately $201,000. Finally, Invictus RG acquired a new position in shares of Alexion Pharmaceuticals during the third quarter valued at approximately $202,000. Institutional investors and hedge funds own 94.04% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Alexion Pharmaceuticals (ALXN) Price Target Cut to $170.00 by Analysts at Citigroup” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/10/alexion-pharmaceuticals-alxn-price-target-cut-to-170-00-by-analysts-at-citigroup.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply